# Aetion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aetion

- Industry: Software
- Headquarters: New York, US
- Website: www.aetion.com
- Total disclosed funding: $185M
- Latest round: Series C (May 11, 2021)
- Investors on record: 15

## About

Founded in 2013 and based in New York, US, Aetion, Inc. provides results-based analytics solutions, including its Aetion evidence platform, that produces validated responses about the best therapies, prices, and outcomes. The company was founded by its President and Chief Science Officer Jeremy Rassen, Allon Rauer, and Sebastian Schneeweiss.  In May 2025, Datavant, Inc., a portfolio company of New Mountain Capital, Thurston Group, LLR Partners, Flex Capital, Cigna Ventures, Transformation Capital, Johnson & Johnson Innovation, Roivant Sciences Ltd., SB Investment Advisors and Founders Fund acquired Aetion, Inc. from New Enterprise Associates, Warburg Pincus, Greenspring Associates, Foundation Medical Partners, Amgen Ventures, Johnson & Johnson Innovation, TransLink Capital, EDBI, Foresite Capital, Lakestar, McKesson Ventures, B Capital Group, Flare Capital Partners, Horizon Healthcare Services, Inc., Sanofi, and UCB S.A.  As of 2021, the company has offices in New York, Boston, Los Angeles, Paris, and its Chief Executive Officer is Carolyn Magill. Aetion provides real-world evidence and outcomes-based analytics solutions for life sciences companies, payers, and at-risk providers. The company’s Aetion Evidence Platform® is a patented rapid-cycle analytics technology that uses the everyday clinical and financial interactions of the healthcare system to provide essential evidence about the effectiveness and value of medical treatments. Aetion also helps payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in inpatient care. The platform is used by medical companies to generate transparent, rapid, and scientifically validated answers on the safety, effectiveness, and value of their product’s life cycle. The company plans to expand its Aetion Evidence Platform®'s capabilities, and advance its global effort in establishing standards for real-world evidence.

## Funding rounds

- Series C, May 11, 2021, $110M — New Enterprise Associates, Warburg Pincus, Foresite Capital, B Capital, Flare Capital Partners
- Series B, Jan 18, 2019, $27M — Greenspring Associates, Johnson & Johnson Innovation, SG Growth Capital
- Series B, Jan 24, 2018, $36M — New Enterprise Associates, Amgen Ventures, UCB S.A., Sanofi, Lakestar, McKesson Ventures, Horizon Healthcare Services, Inc., Flare Capital Partners
- Series A, Feb 22, 2017, $11M — Foundation Medical Partners, Lakestar

## Investors

- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series A
- Lakestar (https://capitalatlas.ai/funds/lakestar) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- UCB S.A. — Series B
- Sanofi — Series B
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series B
- Horizon Healthcare Services, Inc. — Series B
- Flare Capital Partners (https://capitalatlas.ai/funds/flare-capital-partners) — Series B, Series C
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B
- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series C